These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2111065)

  • 21. Prospective evaluation of posttransfusion hepatitis.
    Sirchia G; Giovanetti AM; Parravicini A; Bellobuono A; Mozzi F; Pizzi MN; Almini D
    Transfusion; 1991 May; 31(4):299-302. PubMed ID: 1850568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Incidence of an antigen/antibody system characterizing 1 subgroup of posttransfusion non-A, non-B hepatitis].
    Renger FG; Raabe A; Forster H; Knot E
    Vutr Boles; 1986; 25(5):62-4. PubMed ID: 2433838
    [No Abstract]   [Full Text] [Related]  

  • 23. Post-transfusion non-A, non-B hepatitis in Finland: a prospective study.
    Lagerstedt A; Leikola J; Merikallio E; Ukkonen P
    Scand J Clin Lab Invest; 1982 Nov; 42(7):567-70. PubMed ID: 6818679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low incidence of non-A, non-B post-transfusion hepatitis in London confirmed by hepatitis C virus serology.
    Contreras M; Barbara JA; Anderson CC; Ranasinghe E; Moore C; Brennan MT; Howell DR; Aloysius S; Yardumian A
    Lancet; 1991 Mar; 337(8744):753-7. PubMed ID: 1672391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Anti-HCV antibodies among blood donors in Cantabria. Incidence and relation to transaminase levels].
    Pastor JM; Hermosa V; Ruiz Tagle MA; Zubizarreta A
    Sangre (Barc); 1990 Jun; 35(3):205-7. PubMed ID: 2118687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Lessening the risk of transmission of hepatitis C virus by labile blood products: a role for indirect markers?].
    Jullien AM; Courouce AM; Maniez M; Brevière D; Menault M; Finetti P; Girard M
    Rev Fr Transfus Hemobiol; 1990 Oct; 33(5):355-8. PubMed ID: 2177598
    [No Abstract]   [Full Text] [Related]  

  • 27. [Antibodies to hepatitis B core antigen in blood donors and hepatitis non-A, non-B in blood recipients].
    Sugg U
    Beitr Infusionsther; 1988; 21():177-81. PubMed ID: 2462972
    [No Abstract]   [Full Text] [Related]  

  • 28. Antibodies to hepatitis C virus in non-A, non-B post-transfusion and cryptogenetic chronic liver disease.
    Sansonno D; Dammacco F
    Lancet; 1989 Sep; 2(8666):798-9. PubMed ID: 2571030
    [No Abstract]   [Full Text] [Related]  

  • 29. Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study.
    Aach RD; Szmuness W; Mosley JW; Hollinger FB; Kahn RA; Stevens CE; Edwards VM; Werch J
    N Engl J Med; 1981 Apr; 304(17):989-94. PubMed ID: 6782484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The presence of anti-HCV antibodies in the serum of patients with chronic active hepatitis and antinuclear antibodies.
    Roget M; Buti M; Esteban JI; Esteban R; Guardia J
    Hepatology; 1990 Feb; 11(2):333-5. PubMed ID: 2106476
    [No Abstract]   [Full Text] [Related]  

  • 31. [Public Health Council advisory: prevention of post-transfusion non-A non-B hepatitis; is application of a surrogate test a missed station?].
    Brandt KH
    Ned Tijdschr Geneeskd; 1989 Nov; 133(45):2212-4. PubMed ID: 2509949
    [No Abstract]   [Full Text] [Related]  

  • 32. Posttransfusion hepatitis: clinical features, risk and donor testing.
    Alter HJ
    Prog Clin Biol Res; 1985; 182():47-61. PubMed ID: 3929262
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis.
    Esteban JI; González A; Hernández JM; Viladomiu L; Sánchez C; López-Talavera JC; Lucea D; Martin-Vega C; Vidal X; Esteban R
    N Engl J Med; 1990 Oct; 323(16):1107-12. PubMed ID: 2170839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type 2 autoimmune hepatitis and hepatitis C virus infection.
    Vento S; Di Perri G; Luzzati R; Garofano T; Concia E; Bassetti D
    Lancet; 1990 Apr; 335(8694):921-2. PubMed ID: 1970012
    [No Abstract]   [Full Text] [Related]  

  • 35. Serum alanine aminotransferase (ALT) assay and incidence of posttransfusion non-A,non-B hepatitis.
    Barcena Marugan R; Zamora C; Moreno A; Erdozain Sosa JC; Perez Hernandez F; Lopez San Roman A
    Transfusion; 1989 Oct; 29(8):751. PubMed ID: 2508279
    [No Abstract]   [Full Text] [Related]  

  • 36. Hepatitis C virus infection in kidney transplant patients.
    Marcen R; Pascual J; Orofino L; Fernandez Muñoz R; Teruel JL; Celma ML; Liaño F; Ortuño J
    Transplant Proc; 1992 Feb; 24(1):87-8. PubMed ID: 1371628
    [No Abstract]   [Full Text] [Related]  

  • 37. Antibody to hepatitis-C-virus-related proteins in sera from alanine-aminotransferase-screened blood donors and prospectively studied recipients.
    Widell A; Sundström G; Hansson BG; Moestrup T; Nordenfelt E
    Vox Sang; 1991; 60(1):28-33. PubMed ID: 1647082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibodies to hepatitis C virus in Cuban blood donors.
    Rivero RA; Hedalgo-Gato R; Martinez M; Hernandez P; Ballester JM; Yamaguchi K; Fukuyoshi Y; Kiyokawa T; Takatsuki K
    Vox Sang; 1992; 63(4):285-6. PubMed ID: 1282758
    [No Abstract]   [Full Text] [Related]  

  • 39. Donor transaminase and recipient hepatitis. Impact on blood transfusion services.
    Alter HJ; Purcell RH; Holland PV; Alling DW; Koziol DE
    JAMA; 1981 Aug; 246(6):630-4. PubMed ID: 6788964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-transfusion hepatitis and serum alanine aminotransferase in blood donors.
    N Engl J Med; 1981 Aug; 305(7):403-4. PubMed ID: 6789203
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.